Circulating levels of free and total vascular endothelial growth factor (VEGF)-A, soluble VEGF receptors-1 and -2, and angiogenin during ovarian stimulation in non-human primates and women
article
OA: closed
CC0
⤵ 5 in-corpus citations
Abstract
BACKGROUND: In a prospective study we measured circulating levels of vasoactive factors and their soluble receptors in women undergoing controlled ovarian stimulation (COS) for IVF who were at risk for ovarian hyperstimulation syndrome (OHSS), and compared them to those in a primate model, the rhesus monkey. METHODS: A total of 23 women were enrolled in the study and serum vascular endothelial growth factor (VEGF)-A (free and total), soluble (s)VEGF-R1 and -R2, and angiogenin levels were compared in pregnant and non-pregnant women, and in monkeys, during follicular stimulation, the luteal phase and early pregnancy. RESULTS: VEGF levels were similar during the period of follicular stimulation in pregnant and non-pregnant women, but a significant rise in both free and total VEGF occurred in pregnant women during the luteal phase (P < 0.05). The level of sVEGF-R1 (but not -R2) increased (P < 0.05) following implantation, and the rise in sVEGF-R1 corresponded to an abrupt fall in free (but not total) VEGF. In contrast, total VEGF levels remained similar to those observed on the day of hCG injection. Angiogenin levels tended to decline during follicular stimulation, then increased marginally during the luteal phase and were unchanged in early pregnancy. In contrast to women, free VEGF levels were non-detectable and total levels remained constant through the natural menstrual cycle and COS protocols in monkeys. CONCLUSIONS: The levels of circulating angiogenic factors and soluble receptors demonstrate significant changes during COS cycles and early pregnancy in women. Thus, the systemic effect of these agents is influenced by ligand-receptor protein-binding interactions, and these relationships may exhibit dynamic changes during COS cycles and early pregnancy, and could contribute to the development of OHSS.
My notes (saved in your browser only)
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (49)
- Vascular endothelial growth factor, interleukin-6 and interleukin-2 in serum and follicular fluid of patients with ovarian hyperstimulation syndrome via openalex
- Vascular endothelial growth factor production by human luteinized granulosa cells in vitro via openalex
- doi:10.1210/edrv.18.1.0287 via openalex
- doi:10.1210/jcem.80.6.7775647 via openalex
- doi:10.1016/s0301-2115(00)00460-7 via openalex
- doi:10.1093/molehr/5.12.1115 via openalex
- doi:10.1016/s0015-0282(98)00221-0 via openalex
- doi:10.1677/jme.0.0200363 via openalex
- doi:10.1159/000010270 via openalex
- doi:10.1046/j.1365-2362.1996.830605.x via openalex
- doi:10.1016/s0015-0282(97)81908-5 via openalex
- doi:10.1097/00006254-198906000-00004 via openalex
- doi:10.1095/biolreprod.102.011155 via openalex
- doi:10.1006/bbrc.1996.1355 via openalex
- doi:10.1016/s0015-0282(97)81520-8 via openalex
- W2409624586 via openalex
- doi:10.1093/humrep/14.3.642 via openalex
- doi:10.1677/joe.0.1680409 via openalex
- doi:10.1152/ajpheart.1998.275.3.h1054 via openalex
- doi:10.1055/s-2001-17402 via openalex
- doi:10.1126/science.1312256 via openalex
- doi:10.1016/s0015-0282(00)00670-1 via openalex
- doi:10.1093/humupd/dmg018 via openalex
- doi:10.1093/molehr/6.11.993 via openalex
- doi:10.1210/endo.143.7.8896 via openalex
- doi:10.1093/molehr/4.4.377 via openalex
- doi:10.1016/s0015-0282(00)00492-1 via openalex
- doi:10.1016/s0015-0282(98)00447-6 via openalex
- doi:10.1016/s0140-6736(94)93001-5 via openalex
- doi:10.1093/humrep/15.5.1037 via openalex
- doi:10.1210/jcem.77.6.8263163 via openalex
- doi:10.1172/jci4814 via openalex
- doi:10.1053/beog.2000.0133 via openalex
- doi:10.1093/humrep/14.10.2437 via openalex
- doi:10.1210/jcem.82.7.4169 via openalex
- doi:10.1210/endo-122-5-1876 via openalex
- doi:10.1093/humrep/13.8.2068 via openalex
- doi:10.1095/biolreprod59.6.1540 via openalex
- doi:10.1093/humrep/17.6.1548 via openalex
- doi:10.1016/s0015-0282(98)00484-1 via openalex
- doi:10.1095/biolreprod67.4.1305 via openalex
- doi:10.1016/s0015-0282(16)58152-7 via openalex
- doi:10.1111/j.8755-8920.2000.430105.x via openalex
- doi:10.1095/biolreprod57.6.1451 via openalex
- doi:10.1093/humrep/17.12.3027 via openalex
- doi:10.1016/s0015-0282(99)00294-0 via openalex
- doi:10.1073/pnas.90.22.10705 via openalex
- doi:10.1095/biolreprod67.4.1180 via openalex
- doi:10.1016/0006-291x(92)90483-2 via openalex
Cited by (5)
- Signs of reduced angiogenic activity after surgical removal of deeply infiltrating endometriosis 2010
- Is serum‐soluble vascular endothelial growth factor receptor‐1 of importance in unexplained infertility? 2008
- Vascular endothelial growth factor response to exogenous chorionic gonadotropic hormone in the luteal phase of women with a history of severe ovarian hyperstimulation syndrome 2006
- Ovarielles Überstimulationssyndrom 2006
- Vascular endothelial growth factor expression in the endometrium during the menstrual cycle, implantation window and early pregnancy 2005
Source provenance
- openalex
- last seen: 2026-05-11T06:20:36.346967+00:00
License: CC0
· commercial use OK